{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:54:39Z","timestamp":1793141679893,"version":"4.5.0"},"reference-count":108,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008741","name":"European Alliance of Associations for Rheumatology","doi-asserted-by":"publisher","award":["QoC 025"],"award-info":[{"award-number":["QoC 025"]}],"id":[{"id":"10.13039\/501100008741","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ard.2026.02.009","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T12:11:35Z","timestamp":1774267895000},"page":"1010-1025","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome: 2025 update"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1952-1135","authenticated-orcid":false,"given":"Gulen","family":"Hatemi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8899-9087","authenticated-orcid":false,"given":"Sofia","family":"Ramiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2082-4715","authenticated-orcid":false,"given":"Yesim","family":"Ozguler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinem Nihal","family":"Esatoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Tomasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Barete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bettiol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahram","family":"Bodaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6780-5810","authenticated-orcid":false,"given":"Vladimira","family":"Boyadzhieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7352-1275","authenticated-orcid":false,"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aykut Ferhat","family":"Celik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1827-0311","authenticated-orcid":false,"given":"Omar","family":"Dhrif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9822-0604","authenticated-orcid":false,"given":"Georgina","family":"Ducker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9575-8321","authenticated-orcid":false,"given":"Giacomo","family":"Emmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"G\u00fcl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8385-6861","authenticated-orcid":false,"given":"J\u00f6rg","family":"Henes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9262-005X","authenticated-orcid":false,"given":"Ina","family":"Koetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Krusche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4524-9566","authenticated-orcid":false,"given":"Giuseppe","family":"Lopalco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Moots","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Saadoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Salvarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Sfikakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Stefanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4268-9611","authenticated-orcid":false,"given":"Rosaria","family":"Talarico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilknur","family":"Tugal-Tutkun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugur","family":"Uygunoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Yazici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ard.2026.02.009_bib0001","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.rdc.2023.03.010","article-title":"Beh\u00e7et syndrome","volume":"49","author":"Hatemi","year":"2023","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.ard.2026.02.009_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2025.102597","article-title":"Can we cure Beh\u00e7et syndrome?","volume":"95","author":"Yazici","year":"2025","journal-title":"Curr Opin Immunol"},{"issue":"10431","key":"10.1016\/j.ard.2026.02.009_bib0003","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0140-6736(23)02629-6","article-title":"Beh\u00e7et\u2019s syndrome","volume":"403","author":"Emmi","year":"2024","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ard.2026.02.009_bib0004","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMra2305712","article-title":"Beh\u00e7et\u2019s syndrome","volume":"390","author":"Saadoun","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ard.2026.02.009_bib0005","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/14656566.2022.2155047","article-title":"Current pharmacological solutions for Beh\u00e7et\u2019s syndrome","volume":"24","author":"Ozguler","year":"2023","journal-title":"Expert Opin Pharmacother"},{"issue":"12","key":"10.1016\/j.ard.2026.02.009_bib0006","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1136\/ard.2007.080432","article-title":"EULAR recommendations for the management of Beh\u00e7et disease","volume":"67","author":"Hatemi","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ard.2026.02.009_bib0007","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018 update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.02.009_bib0008","unstructured":"EULAR SOPs\u2014Standard Operating Procedures for Task Forces 2025. [cited 2025 August]. Available from:https:\/\/www.eular.org\/web\/static\/lib\/pdfjs\/web\/viewer.html?file=https:\/\/www.eular.org\/document\/download\/1288\/44fd21f5-69ff-449e-a959-c1398468bfe1\/1198. Accessed March 18, 2026."},{"issue":"12","key":"10.1016\/j.ard.2026.02.009_bib0009","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1093\/rheumatology\/key242","article-title":"Management of major organ involvement of Beh\u00e7et\u2019s syndrome: a systematic review for update of the EULAR recommendations","volume":"57","author":"Ozguler","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.ard.2026.02.009_bib0010","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.semarthrit.2018.05.008","article-title":"Management of skin, mucosa and joint involvement of Beh\u00e7et\u2019s syndrome: a systematic review for update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome","volume":"48","author":"Leccese","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ard.2026.02.009_bib0011","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ard.2026.02.009_bib0012","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2147\/CLEP.S66677","article-title":"Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle-Ottawa Scale and the RTI item bank","volume":"6","author":"Margulis","year":"2014","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.ard.2026.02.009_bib0013","doi-asserted-by":"crossref","unstructured":"Ozguler Y, Esatoglu SN, Tomasson G, Falzon L, Barete S, Bettiol A, et al. Management of major organ involvement in Beh\u00e7et\u2019s syndrome: a systematic literature review informing the 2025 update of the EULAR recommendations. EULAR Rheumatology Open. 2026 (in press).","DOI":"10.1016\/j.ero.2026.02.019"},{"key":"10.1016\/j.ard.2026.02.009_bib0014","doi-asserted-by":"crossref","unstructured":"Esatoglu SN, Ozguler Y, Tomasson G, Falzon L, Barete S, Bettiol A, et al. Management of mucocutaneous and joint involvement of Beh\u00e7et\u2019s syndrome: a systematic literature review informing the 2025 update of the EULAR recommendations. EULAR Rheumatology Open. 2026 (in press).","DOI":"10.1016\/j.ero.2026.02.017"},{"key":"10.1016\/j.ard.2026.02.009_bib0015","unstructured":"Howick JCI, Galsziou P, Explanation of the 2011 Oxford centre for evidence-based medicine (OCEBM) levels of evidence (background document) [Internet]. Oxford Centre for Evidence-Based Medicine. Available from: https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/ocebm-levels-of-evidence. Accessed March 18, 2026."},{"issue":"20","key":"10.1016\/j.ard.2026.02.009_bib0016","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1056\/NEJMoa1816594","article-title":"Trial of apremilast for oral ulcers in Beh\u00e7et\u2019s syndrome","volume":"381","author":"Hatemi","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ard.2026.02.009_bib0017","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002235","article-title":"Impact of apremilast on quality of life in Beh\u00e7et\u2019s syndrome: analysis of the phase 3 RELIEF study","volume":"8","author":"Hatemi","year":"2022","journal-title":"RMD Open"},{"issue":"Suppl 10","key":"10.1016\/j.ard.2026.02.009_bib0018","article-title":"Efficacy of apremilast for the treatment of manifestations of Beh\u00e7et\u2019s syndrome other than oral ulcers, including skin lesions and arthritis [abstract]","volume":"72","author":"Hatemi","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.ard.2026.02.009_bib0019","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nrrheum.2017.208","article-title":"Beh\u00e7et syndrome: a contemporary view","volume":"14","author":"Yazici","year":"2018","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"10.1016\/j.ard.2026.02.009_bib0020","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.3906\/sag-2010-311","article-title":"Risk of tuberculosis is increased in Beh\u00e7et\u2019s disease compared to other rheumatological disorders after anti-TNF\u03b1 treatments: a case series and review of the literature","volume":"51","author":"Gazel","year":"2021","journal-title":"Turk J Med Sci"},{"issue":"12","key":"10.1016\/j.ard.2026.02.009_bib0021","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1093\/rheumatology\/kead628","article-title":"Genetic testing of Beh\u00e7et\u2019s disease using next-generation sequencing to identify monogenic mimics and HLA-B*51","volume":"63","author":"Burleigh","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.ard.2026.02.009_bib0022","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1136\/ard.43.6.783","article-title":"Influence of age of onset and patient\u2019s sex on the prevalence and severity of manifestations of Beh\u00e7et\u2019s syndrome","volume":"43","author":"Yazici","year":"1984","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2026.02.009_bib0023","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00784-021-04047-8","article-title":"Evaluation of diode laser versus topical corticosteroid in management of Beh\u00e7et\u2019s disease-associated oral ulcers: a randomized clinical trial","volume":"26","author":"Nagieb","year":"2022","journal-title":"Clin Oral Investig"},{"issue":"16","key":"10.1016\/j.ard.2026.02.009_bib0025","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1056\/NEJMoa1408684","article-title":"Apremilast for Beh\u00e7et\u2019s syndrome \u2013 a phase 2, placebo-controlled study","volume":"372","author":"Hatemi","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2026.02.009_bib0026","article-title":"Efficacy and safety of infliximab or adalimumab in severe mucocutaneous Beh\u00e7et\u2019s syndrome refractory to traditional immunosuppressants: a 6-month, multicentre, randomised controlled, prospective, parallel group, single-blind trial","author":"Talarico","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ard.2026.02.009_bib0027","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1093\/rheumatology\/keae274","article-title":"Exploring relief for Beh\u00e7et\u2019s disease refractory oral ulcers: a comparison of TNF inhibitors versus apremilast","volume":"64","author":"Lopalco","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.ard.2026.02.009_bib0028","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/archderm.138.4.467","article-title":"Interferon alfa-2a in the treatment of Beh\u00e7et disease: a randomized placebo-controlled and double-blind study","volume":"138","author":"Alpsoy","year":"2002","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.ard.2026.02.009_bib0029","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1056\/NEJM199002013220501","article-title":"A controlled trial of azathioprine in Beh\u00e7et\u2019s syndrome","volume":"322","author":"Yazici","year":"1990","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ard.2026.02.009_bib0030","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jaad.2021.11.045","article-title":"Efficacy and safety of ustekinumab in Beh\u00e7et disease: results from the prospective phase 2 STELABEC trial","volume":"87","author":"London","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.ard.2026.02.009_bib0031","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/art.40912","article-title":"Long-term outcome of ustekinumab therapy for Beh\u00e7et\u2019s disease","volume":"71","author":"Mirouse","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.ard.2026.02.009_bib0034","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1346-8138.2002.tb00263.x","article-title":"Abu-Raghif AR. Dapsone in Beh\u00e7et\u2019s disease: a double-blind, placebo-controlled, cross-over study","volume":"29","author":"Sharquie","year":"2002","journal-title":"J Dermatol"},{"issue":"6","key":"10.1016\/j.ard.2026.02.009_bib0035","doi-asserted-by":"crossref","first-page":"443","DOI":"10.7326\/0003-4819-128-6-199803150-00004","article-title":"Thalidomide in the treatment of the mucocutaneous lesions of the Beh\u00e7et syndrome. A randomized, double-blind, placebo-controlled trial","volume":"128","author":"Hamuryudan","year":"1998","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.ard.2026.02.009_bib0036","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3109\/s10165-009-0200-2","article-title":"Colchicine versus placebo in Beh\u00e7et\u2019s disease: randomized, double-blind, controlled crossover trial","volume":"19","author":"Davatchi","year":"2009","journal-title":"Mod Rheumatol"},{"issue":"11","key":"10.1016\/j.ard.2026.02.009_bib0037","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1002\/1529-0131(200111)44:11<2686::AID-ART448>3.0.CO;2-H","article-title":"A double-blind trial of colchicine in Beh\u00e7et\u2019s syndrome","volume":"44","author":"Yurdakul","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.ard.2026.02.009_bib0038","first-page":"399","article-title":"A double blind study of colchicine in Beh\u00e7et\u2019s disease","volume":"65","author":"Aktulga","year":"1980","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.ard.2026.02.009_bib0039","first-page":"289","article-title":"The effects of adalimumab in Beh\u00e7et disease patients on clinical manifestations and on pro-inflammatory cytokines milieu: long-term follow-up","volume":"22","author":"Braun-Moscovici","year":"2020","journal-title":"Isr Med Assoc J"},{"issue":"9","key":"10.1016\/j.ard.2026.02.009_bib0042","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/1756-185X.13095","article-title":"High-dose intravenous steroid pulse therapy in ocular involvement of Beh\u00e7et\u2019s disease: a pilot double-blind controlled study","volume":"20","author":"Mohammadi","year":"2017","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"10.1016\/j.ard.2026.02.009_bib0043","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/rheumatology\/keq366","article-title":"A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Beh\u00e7et\u2019s disease: a comparative 4-week study","volume":"50","author":"Markomichelakis","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2026.02.009_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109633","article-title":"Intravitreal dexamethasone implants facilitate the management of refractory Beh\u00e7et\u2019s uveitis with vasculitis","volume":"251","author":"Tao","year":"2023","journal-title":"Clin Immunol"},{"issue":"1","key":"10.1016\/j.ard.2026.02.009_bib0045","doi-asserted-by":"crossref","first-page":"44","DOI":"10.4103\/jovr.jovr_254_15","article-title":"Characteristics of macular edema in Beh\u00e7et disease after intravitreal bevacizumab injection","volume":"12","author":"Ghassemi","year":"2017","journal-title":"J Ophthalmic Vis Res"},{"key":"10.1016\/j.ard.2026.02.009_bib0046","article-title":"The efficacy of adalimumab as an initial treatment in patients with Beh\u00e7et\u2019s retinal vasculitis","volume":"12","author":"Yang","year":"2021","journal-title":"Front Pharmacol"},{"issue":"10","key":"10.1016\/j.ard.2026.02.009_bib0047","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N Engl J Med"},{"issue":"10050","key":"10.1016\/j.ard.2026.02.009_bib0048","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ard.2026.02.009_bib0049","doi-asserted-by":"crossref","first-page":"e780","DOI":"10.1016\/S2665-9913(24)00194-2","article-title":"Combinations of immunomodulatory agents for prevention of uveitis relapse in patients with severe Beh\u00e7et\u2019s disease already on corticosteroid therapy: a randomised, open-label, head-to-head trial","volume":"6","author":"Zhong","year":"2024","journal-title":"Lancet Rheumatol"},{"issue":"5","key":"10.1016\/j.ard.2026.02.009_bib0050","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1093\/rheumatology\/keae585","article-title":"Infliximab vs interferon-alpha in the treatment of Beh\u00e7et\u2019s syndrome: clinical data from the BIO-Beh\u00e7et\u2019s randomized controlled trial","volume":"64","author":"Moots","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2026.02.009_bib0051","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.699903","article-title":"Comparison of the safety and efficacy of interferon alpha-2a and cyclosporine-A when combined with glucocorticoid in the treatment of refractory Beh\u00e7et\u2019s uveitis: a randomized controlled prospective study","volume":"12","author":"Qian","year":"2021","journal-title":"Front Pharmacol"},{"issue":"23","key":"10.1016\/j.ard.2026.02.009_bib0052","doi-asserted-by":"crossref","first-page":"7388","DOI":"10.3390\/jcm13237388","article-title":"Comparative study of adalimumab, infliximab and certolizumab pegol in the treatment of cystoid macular edema due to Beh\u00e7et\u2019s disease","volume":"13","author":"Barroso-Garc\u00eda","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.ard.2026.02.009_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152153","article-title":"Anti-TNF vs tocilizumab in refractory uveitic cystoid macular edema due to Beh\u00e7et\u2019s disease. Multicenter study of 49 patients","volume":"58","author":"Barroso-Garc\u00eda","year":"2023","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.ard.2026.02.009_bib0054","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1002\/art.41026","article-title":"Comparative study of infliximab versus adalimumab in refractory uveitis due to Beh\u00e7et\u2019s disease: National Multicenter Study of 177 cases","volume":"71","author":"Atienza-Mateo","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 3","key":"10.1016\/j.ard.2026.02.009_bib0055","doi-asserted-by":"crossref","first-page":"S521","DOI":"10.4103\/IJO.IJO_2011_23","article-title":"Comparative results of use and switching of anti-TNF-alpha agents in adult Beh\u00e7et\u2019s uveitis","volume":"72","author":"Mesen","year":"2024","journal-title":"Indian J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ard.2026.02.009_bib0056","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/09273948.2020.1791346","article-title":"Anti-TNF-alpha therapy for refractory uveitis associated with Beh\u00e7et\u2019s syndrome and sarcoidosis: a single center study of 131 patients","volume":"30","author":"Kunimi","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"issue":"6","key":"10.1016\/j.ard.2026.02.009_bib0057","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1007\/s10067-018-4092-4","article-title":"Predictors of sustained clinical response in patients with Beh\u00e7et\u2019s disease-related uveitis treated with infliximab and adalimumab","volume":"37","author":"Fabiani","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ard.2026.02.009_bib0058","article-title":"Ten-year follow-up of infliximab treatment for uveitis in Beh\u00e7et disease patients: a multicenter retrospective study","volume":"10","author":"Takeuchi","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"10.1016\/j.ard.2026.02.009_bib0059","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13075-018-1793-7","article-title":"Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Beh\u00e7et\u2019s disease: a large-scale, long-term postmarketing surveillance in Japan","volume":"21","author":"Ohno","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.ard.2026.02.009_bib0060","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3109\/09273948.2012.713159","article-title":"Comparison of presenting features and three-year disease course in Turkish patients with Beh\u00e7et uveitis who presented in the early 1990s and the early 2000s","volume":"20","author":"Cingu","year":"2012","journal-title":"Ocul Immunol Inflamm"},{"issue":"2","key":"10.1016\/j.ard.2026.02.009_bib0061","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/09273948.2024.2383315","article-title":"Development of posterior uveitis in Beh\u00e7et syndrome patients with vitreous cells at baseline","volume":"33","author":"Ucar","year":"2025","journal-title":"Ocul Immunol Inflamm"},{"issue":"4","key":"10.1016\/j.ard.2026.02.009_bib0062","doi-asserted-by":"crossref","first-page":"219","DOI":"10.4103\/0974-9233.58425","article-title":"Beh\u00e7et\u2019s uveitis","volume":"16","author":"Tugal-Tutkun","year":"2009","journal-title":"Middle East Afr J Ophthalmol"},{"issue":"8","key":"10.1016\/j.ard.2026.02.009_bib0063","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1080\/09273948.2019.1641611","article-title":"The relationship between fluorescein angiography leakage after infliximab therapy and relapse of ocular inflammatory attacks in ocular Beh\u00e7et\u2019s disease patients","volume":"28","author":"Shirahama","year":"2020","journal-title":"Ocul Immunol Inflamm"},{"issue":"9","key":"10.1016\/j.ard.2026.02.009_bib0064","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1093\/rheumatology\/kez598","article-title":"Long term follow-up of Beh\u00e7et\u2019s syndrome patients treated with cyclophosphamide","volume":"59","author":"Gurcan","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2026.02.009_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109682","article-title":"Infliximab for vascular involvement in Beh\u00e7et\u2019s syndrome","volume":"253","author":"Hatemi","year":"2023","journal-title":"Clin Immunol"},{"issue":"6","key":"10.1016\/j.ard.2026.02.009_bib0066","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1177\/1708538120927701","article-title":"Infliximab treatment in refractory vascular Beh\u00e7et\u2019s disease: a single-center experience","volume":"28","author":"Kehribar","year":"2020","journal-title":"Vascular"},{"issue":"2","key":"10.1016\/j.ard.2026.02.009_bib0067","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/1756-185X.13778","article-title":"Efficacy of TNF\u03b1 inhibitors for refractory vascular Beh\u00e7et\u2019s disease: a multicenter observational study of 27 patients and a review of the literature","volume":"23","author":"Aksoy","year":"2020","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.ard.2026.02.009_bib0068","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.clim.2018.08.004","article-title":"Efficacy of anti-TNF alpha in severe and refractory major vessel involvement of Beh\u00e7et\u2019s disease: a multicenter observational study of 18 patients","volume":"197","author":"Desbois","year":"2018","journal-title":"Clin Immunol"},{"issue":"11","key":"10.1016\/j.ard.2026.02.009_bib0069","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300354","article-title":"Infliximab versus cyclophosphamide for severe Beh\u00e7et\u2019s syndrome","volume":"3","author":"Saadoun","year":"2024","journal-title":"NEJM Evid."},{"issue":"5","key":"10.1016\/j.ard.2026.02.009_bib0073","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.surg.2015.11.022","article-title":"Outcomes of vascular intervention and use of perioperative medications for nonpulmonary aneurysms in Beh\u00e7et disease","volume":"159","author":"Liu","year":"2016","journal-title":"Surgery"},{"issue":"5","key":"10.1016\/j.ard.2026.02.009_bib0074","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.jvs.2020.01.076","article-title":"Factors influencing the recurrence of arterial involvement after surgical repair in Beh\u00e7et disease","volume":"72","author":"Gaudric","year":"2020","journal-title":"J Vasc Surg"},{"issue":"1","key":"10.1016\/j.ard.2026.02.009_bib0075","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jvs.2011.07.049","article-title":"Management and prognosis of nonpulmonary large arterial disease in patients with Beh\u00e7et disease","volume":"55","author":"Tuzun","year":"2012","journal-title":"J Vasc Surg"},{"issue":"1","key":"10.1016\/j.ard.2026.02.009_bib0076","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/MD.0b013e318242ff37","article-title":"Pulmonary artery involvement and associated lung disease in Beh\u00e7et disease: a series of 47 patients","volume":"91","author":"Seyahi","year":"2012","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.ard.2026.02.009_bib0077","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1024\/0301-1526.32.2.75","article-title":"Arterial lesions in Beh\u00e7et\u2019s disease","volume":"32","author":"Saba","year":"2003","journal-title":"Vasa"},{"issue":"1","key":"10.1016\/j.ard.2026.02.009_bib0078","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/rheumatology\/33.1.48","article-title":"Pulmonary arterial aneurysms in Beh\u00e7et\u2019s syndrome: a report of 24 cases","volume":"33","author":"Hamuryudan","year":"1994","journal-title":"Br J Rheumatol"},{"issue":"4","key":"10.1016\/j.ard.2026.02.009_bib0079","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1093\/rheumatology\/kez352","article-title":"Clinical course of acute deep vein thrombosis of the legs in Beh\u00e7et\u2019s syndrome","volume":"59","author":"Ozguler","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.ard.2026.02.009_bib0080","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1002\/art.40531","article-title":"Adalimumab-based treatment versus disease-modifying antirheumatic drugs for venous thrombosis in Beh\u00e7et\u2019s syndrome: a retrospective study of seventy patients with vascular involvement","volume":"70","author":"Emmi","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.ard.2026.02.009_bib0081","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/art.24393","article-title":"Cerebral venous thrombosis in Beh\u00e7et\u2019s disease","volume":"61","author":"Saadoun","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.ard.2026.02.009_bib0082","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10067-007-0685-z","article-title":"Treatment of venous thrombosis associated with Beh\u00e7et\u2019s disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation","volume":"27","author":"Ahn","year":"2008","journal-title":"Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.ard.2026.02.009_bib0083","doi-asserted-by":"crossref","first-page":"e494","DOI":"10.1097\/MD.0000000000000494","article-title":"Beh\u00e7et disease with vascular involvement: effects of different therapeutic regimens on the incidence of new relapses","volume":"94","author":"Alibaz-Oner","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"10.1016\/j.ard.2026.02.009_bib0084","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1007\/s10067-021-05748-x","article-title":"Clinical characteristics of pulmonary artery involvement in patients with Beh\u00e7et\u2019s syndrome: single-centre experience of 61 patients","volume":"40","author":"Eroglu","year":"2021","journal-title":"Clin Rheumatol"},{"issue":"8","key":"10.1016\/j.ard.2026.02.009_bib0085","first-page":"575","article-title":"Evaluation of clinical features and treatment responses in cardiac and vascular involvement of Beh\u00e7et\u2019s disease","volume":"15","author":"Yadigaroglu","year":"2024","journal-title":"Ann Clin Anal Med"},{"issue":"4","key":"10.1016\/j.ard.2026.02.009_bib0086","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/10815589241232368","article-title":"Does anticoagulation in combination with immunosuppressive therapy prevent recurrent thrombosis in Beh\u00e7et\u2019s disease?","volume":"72","author":"Erol","year":"2024","journal-title":"J Investig Med"},{"issue":"8","key":"10.1016\/j.ard.2026.02.009_bib0087","first-page":"1491","article-title":"Vascular Beh\u00e7et\u2019s disease: a comparative study from Turkey and France","volume":"40","author":"Alibaz-Oner","year":"2022","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.ard.2026.02.009_bib0088","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102783","article-title":"Direct oral anticoagulant for venous thrombosis in Beh\u00e7et\u2019s syndrome","volume":"20","author":"Vautier","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.ard.2026.02.009_bib0089","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.jvsv.2021.02.007","article-title":"Predictors for the risk and severity of post-thrombotic syndrome in vascular Beh\u00e7et\u2019s disease","volume":"9","author":"Aksoy","year":"2021","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"issue":"3","key":"10.1016\/j.ard.2026.02.009_bib0090","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jvsv.2016.01.003","article-title":"Post-thrombotic syndrome and venous disease-specific quality of life in patients with vascular Beh\u00e7et\u2019s disease","volume":"4","author":"Alibaz-Oner","year":"2016","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"issue":"8","key":"10.1016\/j.ard.2026.02.009_bib0091","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/RHU.0000000000002137","article-title":"Anticoagulant treatment may decrease the relapse rate of pulmonary arterial involvement in Beh\u00e7et\u2019s disease","volume":"30","author":"Abacar","year":"2024","journal-title":"J Clin Rheumatol"},{"issue":"11","key":"10.1016\/j.ard.2026.02.009_bib0092","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1093\/rheumatology\/keu233","article-title":"Vascular involvement in Beh\u00e7et\u2019s syndrome: a retrospective analysis of associations and the time course","volume":"53","author":"Tascilar","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2026.02.009_bib0093","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2025.152643","article-title":"Venous ulcers in Beh\u00e7et syndrome","volume":"71","author":"Karakoc","year":"2025","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.ard.2026.02.009_bib0094","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/ced.14539","article-title":"Efficacy of maggot debridement therapy on refractory leg ulcers of Beh\u00e7et disease: an open-label study","volume":"46","author":"Kecici","year":"2021","journal-title":"Clin Exp Dermatol"},{"issue":"16","key":"10.1016\/j.ard.2026.02.009_bib0095","doi-asserted-by":"crossref","first-page":"e3348","DOI":"10.1097\/MD.0000000000003348","article-title":"Characteristics, treatment, and long-term outcome of gastrointestinal involvement in Beh\u00e7et\u2019s syndrome: a strobe-compliant observational study from a dedicated multidisciplinary center","volume":"95","author":"Hatemi","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"10.1016\/j.ard.2026.02.009_bib0096","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1055\/s-2000-9012","article-title":"Prediction of the clinical course of Beh\u00e7et\u2019s colitis according to macroscopic classification by colonoscopy","volume":"32","author":"Kim","year":"2000","journal-title":"Endoscopy"},{"issue":"6 Suppl 94","key":"10.1016\/j.ard.2026.02.009_bib0097","first-page":"S129","article-title":"TNF-alpha antagonists and thalidomide for the management of gastrointestinal Beh\u00e7et\u2019s syndrome refractory to the conventional treatment modalities: a case series and review of the literature","volume":"33","author":"Hatemi","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ard.2026.02.009_bib0098","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X221124014","article-title":"Tofacitinib as an alternative therapy for refractory intestinal Beh\u00e7et\u2019s syndrome","volume":"14","author":"Zou","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.ard.2026.02.009_bib0099","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109241","article-title":"Baricitinib for the treatment of intestinal Beh\u00e7et\u2019s disease: a pilot study","volume":"247","author":"Liu","year":"2023","journal-title":"Clin Immunol"},{"issue":"7","key":"10.1016\/j.ard.2026.02.009_bib0100","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1002\/ibd.21517","article-title":"Prognostic factors and long-term clinical outcomes for surgical patients with intestinal Beh\u00e7et\u2019s disease","volume":"17","author":"Jung","year":"2011","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"10.1016\/j.ard.2026.02.009_bib0101","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/DCR.0b013e318238b57e","article-title":"Early versus late surgery in patients with intestinal Beh\u00e7et disease","volume":"55","author":"Jung","year":"2012","journal-title":"Dis Colon Rectum"},{"issue":"23","key":"10.1016\/j.ard.2026.02.009_bib0102","doi-asserted-by":"crossref","first-page":"e3550","DOI":"10.1097\/MD.0000000000003550","article-title":"Efficacy of anti-TNF\u03b1 in severe and refractory neuro-Beh\u00e7et disease: an observational study","volume":"95","author":"Desbois","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"10.1016\/j.ard.2026.02.009_bib0103","first-page":"2040","article-title":"Infliximab for parenchymal neuro-Beh\u00e7et\u2019s syndrome: case series and meta-analysis","volume":"42","author":"Wang","year":"2024","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"10.1016\/j.ard.2026.02.009_bib0104","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1111\/1756-185X.14209","article-title":"Infliximab therapy in parenchymal neuro-Beh\u00e7et\u2019s disease: a single-center experience","volume":"24","author":"Yalcin Kehribar","year":"2021","journal-title":"Int J Rheum Dis"},{"issue":"5","key":"10.1016\/j.ard.2026.02.009_bib0105","doi-asserted-by":"crossref","first-page":"e258","DOI":"10.1212\/NXI.0000000000000258","article-title":"Infliximab is a plausible alternative for neurologic complications of Beh\u00e7et disease","volume":"3","author":"Zeydan","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"10","key":"10.1016\/j.ard.2026.02.009_bib0106","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1007\/s10067-024-07118-9","article-title":"Long-term outcomes of infliximab treatment in neuro-Beh\u00e7et syndrome: a single-center retrospective study","volume":"43","author":"Rabia","year":"2024","journal-title":"Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.ard.2026.02.009_bib0107","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2169\/internalmedicine.1969-23","article-title":"Effect of infliximab on chronic progressive Neuro-Beh\u00e7et\u2019s disease: influence of the timing of introduction on the patient outcome","volume":"63","author":"Hirohata","year":"2024","journal-title":"Intern Med"},{"issue":"7","key":"10.1016\/j.ard.2026.02.009_bib0108","doi-asserted-by":"crossref","first-page":"916","DOI":"10.3899\/jrheum.221106","article-title":"Tocilizumab in Beh\u00e7et disease: a multicenter study of 30 patients","volume":"50","author":"Khitri","year":"2023","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.ard.2026.02.009_bib0109","first-page":"1575","article-title":"IL-6 blockade for Beh\u00e7et\u2019s disease: review on 31 anti-TNF naive and 45 anti-TNF experienced patients","volume":"40","author":"Arida","year":"2022","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.ard.2026.02.009_bib0110","doi-asserted-by":"crossref","first-page":"223","DOI":"10.5152\/eurjrheum.2021.20160","article-title":"Use of non-TNF biologics for the treatment of neuro-Beh\u00e7et\u2019s disease: literature review and 2 refractory cases of monoclonal anti-TNFs treated with tocilizumab","volume":"8","author":"Karabulut","year":"2021","journal-title":"Eur J Rheumatol"},{"key":"10.1016\/j.ard.2026.02.009_bib0111","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20971908","article-title":"Tocilizumab in the treatment of severe and refractory parenchymal neuro-Beh\u00e7et\u2019s syndrome: case series and literature review","volume":"12","author":"Liu","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"10","key":"10.1016\/j.ard.2026.02.009_bib0112","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1093\/rheumatology\/ket130","article-title":"Lack of efficacy of tocilizumab in mucocutaneous Beh\u00e7et\u2019s syndrome: report of two cases","volume":"52","author":"Diamantopoulos","year":"2013","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.ard.2026.02.009_bib0113","doi-asserted-by":"crossref","first-page":"301","DOI":"10.5217\/ir.2020.00013","article-title":"Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Beh\u00e7et\u2019s disease: results from a large real-world observational study","volume":"19","author":"Suzuki","year":"2021","journal-title":"Intest Res"},{"issue":"5","key":"10.1016\/j.ard.2026.02.009_bib0114","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1136\/bjophthalmol-2017-310733","article-title":"Cumulative retention rate of adalimumab in patients with Beh\u00e7et\u2019s disease-related uveitis: a four-year follow-up study","volume":"102","author":"Fabiani","year":"2018","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ard.2026.02.009_bib0115","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10067-016-3417-4","article-title":"Adalimumab effectiveness in Beh\u00e7et\u2019s disease: short and long-term data from a multicenter retrospective observational study","volume":"36","author":"Vitale","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.ard.2026.02.009_bib0116","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/acr.24511","article-title":"Core set of domains for outcome measures in Beh\u00e7et\u2019s syndrome","volume":"74","author":"Hatemi","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000349672600083X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000349672600083X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T20:30:24Z","timestamp":1780864224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000349672600083X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":108,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S000349672600083X"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2026.02.009","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome: 2025 update","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2026.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}